Taiwan
· Delayed Price · Currency is TWD Senhwa Biosciences Statistics
Total Valuation
Senhwa Biosciences has a market cap or net worth of TWD 4.04 billion. The enterprise value is 2.96 billion.
| Market Cap | 4.04B |
| Enterprise Value | 2.96B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Senhwa Biosciences has 89.19 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 89.19M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.04% |
| Owned by Institutions (%) | 0.17% |
| Float | 68.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.65 |
| P/TBV Ratio | 3.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.97 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.44 |
Financial Position
The company has a current ratio of 40.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 40.38 |
| Quick Ratio | 40.06 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -510.05 |
Financial Efficiency
Return on equity (ROE) is -23.69% and return on invested capital (ROIC) is -15.30%.
| Return on Equity (ROE) | -23.69% |
| Return on Assets (ROA) | -15.10% |
| Return on Capital (ROIC) | -15.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.17% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -18.17% |
| 50-Day Moving Average | 49.40 |
| 200-Day Moving Average | 46.66 |
| Relative Strength Index (RSI) | 40.77 |
| Average Volume (20 Days) | 263,975 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Senhwa Biosciences had revenue of TWD 1.00 million and -297.21 million in losses. Loss per share was -3.33.
| Revenue | 1.00M |
| Gross Profit | 512,000 |
| Operating Income | -310.62M |
| Pretax Income | -295.95M |
| Net Income | -297.21M |
| EBITDA | -308.46M |
| EBIT | -310.62M |
| Loss Per Share | -3.33 |
Balance Sheet
The company has 1.09 billion in cash and 16.94 million in debt, giving a net cash position of 1.07 billion or 12.02 per share.
| Cash & Cash Equivalents | 1.09B |
| Total Debt | 16.94M |
| Net Cash | 1.07B |
| Net Cash Per Share | 12.02 |
| Equity (Book Value) | 1.11B |
| Book Value Per Share | 12.39 |
| Working Capital | 1.09B |
Cash Flow
In the last 12 months, operating cash flow was -281.83 million and capital expenditures -1.95 million, giving a free cash flow of -283.79 million.
| Operating Cash Flow | -281.83M |
| Capital Expenditures | -1.95M |
| Free Cash Flow | -283.79M |
| FCF Per Share | -3.18 |
Margins
| Gross Margin | 51.20% |
| Operating Margin | -31,061.80% |
| Pretax Margin | -29,594.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -28,378.70% |
Dividends & Yields
Senhwa Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
| Earnings Yield | -7.36% |
| FCF Yield | -7.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Senhwa Biosciences has an Altman Z-Score of 70.12.
| Altman Z-Score | 70.12 |
| Piotroski F-Score | n/a |